Biocon's biosimilar strategy is playing out well and the company is set to enter developed or regulated markets with a basket of biosimilar products in next three years. The company will enter these markets at a time when patent expires in these ...

Syngene has played an instrumental role in boosting Biocon's revenue and profitability in the past few years when growth in the biopharmaceutical business remained flat. Photo: Hemant Mishra/Mint Biocon Ltd, India's biggest biotechnology ...

BENGALURU: Uncertainty is brewing at Visvesvaraya Industrial and Technological Museum (VITM), following a proposal by Biocon Chairman Kiran Mazumdar-Shaw to adopt it under its Corporate Social Responsibility programme. These fears were in full ...

Drug maker says better poised to licence and position its novel molecule Itolizumab, which has a Cuban origin Bangalore-based Biocon hopes that the thaw in bilateral relations between the US and Cuba offers the company a "better ...

Comment · print · T T T+· T- TOPICS Bio-pharma major Biocon reported a 23 per cent jump in its net profit at Rs.126 crore for the first quarter ended June 30, 2015 of the FY 16. The Bengaluru-based company's net revenue for the ...

MUMBAI: Shares of biotechnology major Biocon today ended nearly 2 per cent higher after the company reported a 23 per cent growth in consolidated net profit for the quarter ended June 30, 2015. The stock ended the day with a gain of 1.66 per cent at Rs 466.15 ...

The 'Adopt a Tourism Destination' plan of the Tourism department has received a positive response. The department has managed to bring big names from India and Karnataka on board to adopt popular destinations and give them a facelift. Jindal Steel and Power ...

More than 100 Bengaluru citizens who at some point of time studied in Australia came together to form an Australian Alumni Association, Bengaluru Chapter on Friday. One of the most prominent personalities in the city, Kiran Mazumdar Shaw -- also an ...